Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Denali Therapeutics (NASDAQ:DNLI) had its price target lifted by stock analysts at The Goldman Sachs Group from $35.00 to $40.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s target price points to a potential upside of 120.26% from the stock’s current price.

A number of other equities research analysts have also recently commented on DNLI. UBS Group began coverage on shares of Denali Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating for the company. HC Wainwright increased their price objective on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday. Wedbush reduced their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Jefferies Financial Group restated a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research note on Monday, March 2nd. Finally, Wolfe Research assumed coverage on Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $18.16 on Thursday. The business has a 50 day moving average of $20.43 and a 200-day moving average of $17.83. The company has a market capitalization of $2.88 billion, a P/E ratio of -6.11 and a beta of 1.02. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same period last year, the company earned ($0.67) earnings per share. On average, equities research analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity

In other news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently made changes to their positions in the business. Foresite Capital Management VI LLC purchased a new position in shares of Denali Therapeutics in the 3rd quarter worth about $14,520,000. AlphaQuest LLC grew its position in Denali Therapeutics by 224.1% during the third quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock valued at $1,081,000 after buying an additional 51,458 shares during the period. Aberdeen Group plc increased its holdings in Denali Therapeutics by 23.4% during the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock worth $16,169,000 after buying an additional 210,835 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Denali Therapeutics by 18.5% during the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock worth $18,458,000 after buying an additional 198,207 shares during the last quarter. Finally, Holocene Advisors LP raised its position in Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after acquiring an additional 2,732,540 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.